Ortivus AB (publ) (ORTI-B.ST)
SEK 1.48
(-6.62%)
SEK 1.48
(-6.62%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.41 SEK | -415.38% |
| 2022 | 0.13 SEK | -38.1% |
| 2021 | 0.21 SEK | -19.23% |
| 2020 | 0.26 SEK | 160.47% |
| 2019 | -0.43 SEK | 0.0% |
| 2018 | -0.43 SEK | -10.26% |
| 2017 | -0.39 SEK | -39.29% |
| 2016 | -0.28 SEK | -27.27% |
| 2015 | -0.22 SEK | -598.87% |
| 2014 | 0.04 SEK | 110.26% |
| 2013 | -0.43 SEK | -719.6% |
| 2012 | 0.07 SEK | 106.03% |
| 2011 | -1.15 SEK | -69.12% |
| 2010 | -0.68 SEK | -21.43% |
| 2009 | -0.56 SEK | 73.33% |
| 2008 | -2.10 SEK | -12.3% |
| 2007 | -1.87 SEK | 65.18% |
| 2006 | -5.37 SEK | -562.96% |
| 2005 | -0.81 SEK | -195.29% |
| 2004 | 0.85 SEK | 142.86% |
| 2003 | 0.35 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.05 SEK | 22.49% |
| 2024 Q2 | -0.19 SEK | -290.95% |
| 2023 Q3 | -0.25 SEK | -127.27% |
| 2023 Q1 | -0.00 SEK | -119.57% |
| 2023 FY | - SEK | -415.38% |
| 2023 Q4 | -0.06 SEK | 74.92% |
| 2023 Q2 | -0.11 SEK | -12122.22% |
| 2022 Q1 | 0.04 SEK | 11.0% |
| 2022 Q2 | 0.08 SEK | 77.7% |
| 2022 Q3 | 0.01 SEK | -93.41% |
| 2022 Q4 | 0.00 SEK | -11.54% |
| 2022 FY | - SEK | -38.1% |
| 2021 Q3 | 0.06 SEK | -14.29% |
| 2021 Q2 | 0.07 SEK | 75.0% |
| 2021 FY | - SEK | -19.23% |
| 2021 Q1 | 0.04 SEK | -19.19% |
| 2021 Q4 | 0.04 SEK | -33.33% |
| 2020 Q3 | 0.03 SEK | -80.0% |
| 2020 Q1 | 0.02 SEK | 147.39% |
| 2020 Q2 | 0.15 SEK | 650.0% |
| 2020 FY | - SEK | 160.47% |
| 2020 Q4 | 0.05 SEK | 65.0% |
| 2019 Q4 | -0.04 SEK | 54.87% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q3 | -0.09 SEK | 28.08% |
| 2019 Q2 | -0.13 SEK | 31.58% |
| 2019 Q1 | -0.19 SEK | -58.33% |
| 2018 FY | - SEK | -10.26% |
| 2018 Q1 | -0.12 SEK | -94.49% |
| 2018 Q2 | -0.15 SEK | -25.0% |
| 2018 Q3 | -0.03 SEK | 77.8% |
| 2018 Q4 | -0.12 SEK | -260.36% |
| 2017 Q4 | -0.06 SEK | 43.91% |
| 2017 Q3 | -0.11 SEK | 8.33% |
| 2017 Q2 | -0.12 SEK | -20.0% |
| 2017 Q1 | -0.10 SEK | -423.62% |
| 2017 FY | - SEK | -39.29% |
| 2016 Q1 | -0.15 SEK | -156.85% |
| 2016 FY | - SEK | -27.27% |
| 2016 Q4 | 0.03 SEK | 672.5% |
| 2016 Q3 | 0.00 SEK | 102.86% |
| 2016 Q2 | -0.14 SEK | 6.67% |
| 2015 Q2 | -0.00 SEK | -157.14% |
| 2015 Q3 | -0.16 SEK | -4344.44% |
| 2015 Q1 | 0.01 SEK | 105.73% |
| 2015 Q4 | -0.06 SEK | 63.5% |
| 2015 FY | - SEK | -598.87% |
| 2014 Q1 | 0.06 SEK | 127.05% |
| 2014 FY | - SEK | 110.26% |
| 2014 Q3 | 0.05 SEK | 14.29% |
| 2014 Q4 | -0.11 SEK | -318.25% |
| 2014 Q2 | 0.04 SEK | -22.36% |
| 2013 Q3 | -0.07 SEK | 18.22% |
| 2013 Q4 | -0.21 SEK | -188.86% |
| 2013 FY | - SEK | -719.6% |
| 2013 Q1 | -0.06 SEK | 3.82% |
| 2013 Q2 | -0.09 SEK | -60.47% |
| 2012 Q2 | 0.10 SEK | 208.81% |
| 2012 FY | - SEK | 106.03% |
| 2012 Q1 | -0.09 SEK | 75.16% |
| 2012 Q3 | 0.11 SEK | 10.0% |
| 2012 Q4 | -0.06 SEK | -152.36% |
| 2011 Q2 | -0.36 SEK | -140.0% |
| 2011 Q3 | -0.27 SEK | 25.0% |
| 2011 Q4 | -0.37 SEK | -37.04% |
| 2011 FY | - SEK | -69.12% |
| 2011 Q1 | -0.15 SEK | -15.38% |
| 2010 Q2 | -0.33 SEK | -6370.59% |
| 2010 Q3 | -0.21 SEK | 36.36% |
| 2010 FY | - SEK | -21.43% |
| 2010 Q4 | -0.13 SEK | 38.1% |
| 2010 Q1 | -0.01 SEK | 0.0% |
| 2009 FY | - SEK | 73.33% |
| 2008 FY | - SEK | -12.3% |
| 2007 FY | - SEK | 65.18% |
| 2006 FY | - SEK | -562.96% |
| 2005 FY | - SEK | -195.29% |
| 2004 FY | - SEK | 142.86% |
| 2003 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| AddLife AB (publ) | 1.56 SEK | 126.282% |
| Biotage AB (publ) | 3.33 SEK | 112.312% |
| Bonesupport Holding AB (publ) | 3.77 SEK | 110.875% |
| Doxa AB (publ) | 0.60 SEK | 168.333% |
| Elekta AB (publ) | 3.41 SEK | 112.023% |
| iZafe Group AB (publ) | -0.14 SEK | -192.857% |
| Ortivus AB (publ) | -0.41 SEK | -0.0% |
| Q-linea AB (publ) | -3.48 SEK | 88.218% |
| S2Medical AB (publ) | -0.14 SEK | -192.857% |
| Synsam AB (publ) | 2.09 SEK | 119.617% |